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Abstract
Background: Chronic edema/lymphedema is defined as edema present for more than 3 months. It is under-
recognized and undertreated. The International Lymphedema Framework developed an international study,
Lymphedema Impact and Prevalence International (LIMPRINT), to estimate the prevalence and impact of
chronic edema in heterogeneous populations. Canada participated in this study.
Methods and Results: Participants were recruited from an outpatient chronic wound management clinic. At a
study visit, the following tools were administered: The Core Tool, Demographics and Disability assessment
(WHODAS 2.0), Quality-of-life assessment (LYMQOL + EQ-5D), Details of swelling, Wound assessment, and
Cancer. Data were entered into an international database (Clindex), and country-specific data were analyzed.
Sixty-eight subjects were enrolled. Fifty-seven percent were males and 43% females. More than 90% were older
than 45 years. Only 7.35% had primary lymphedema. Most had lower extremity edema (65 of 68). Over half
(47.06%) were morbidly obese with body mass index of >40. The most common underlying condition was
venous disease. Only 8 of 68 had a history of cancer. While 72.06% had a history of cellulitis, only 10.2% had
been hospitalized in the past year. 39.71% had an open wound. More than 75% had received multilayer
bandaging, compression garments, wound dressings, and extensive counseling. Few had received manual
lymphatic drainage, which is not funded. Disability was less than expected.
Conclusion: Chronic edema/lymphedema is an underrecognized condition. These data and the wider LIMPRINT
study are important tools to advocate for wider recognition and funding of treatment by health care systems.
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Introduction
Chronic edema is defined as edema present for morethan 3 months, affecting any site of the body irrespective
of underlying etiology or concurrent comorbidities.1 Many
authors now define all chronic edema as lymphedema.2 In the
peripheral tissue, capillaries and the lymphatics are inti-
mately associated and function as a coordinated unit to
manage tissue fluid. Thus, any chronic edema will involve
lymphatic dysfunction. Lymphedema has been described as a
hidden epidemic. Worldwide, it is underrecognized and un-
dertreated. It is a chronic condition and is best treated using
the chronic disease models that focus on self-management
with professional support for assessment, treatment recom-
mendations, and monitoring.3
A recent systematic review has indicated that there is a
dearth of population-based epidemiological studies to define
the prevalence of chronic edema and little robust evidence of
the cost and clinical effectiveness of different models of
care.4 It is therefore difficult for those who commission ser-
vices, and other health care agencies, to determine treat-
ment priorities and to justify the provision of clinical services
for people with chronic edema or to reimburse care costs.
Recently, the Canadian Lymphedema Framework (www
.canadalymph.ca) estimated the prevalence of lymphedema
in Canada by using available data for the prevalence of
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conditions known to be associated with lymphedema. The
estimated number of Canadians living with lymphedema is 1
million giving a prevalence of 2.8%.
The Lymphedema Impact and Prevalence
International Study
This international study was designed to estimate the
prevalence and impact of chronic edema in heterogeneous
populations.
Primary aim
To determine the prevalence and functional impact of
chronic edema in the adult population at a national and in-
ternational level using modular epidemiological tools.
Secondary aims
1. To identify, using a case ascertainment questionnaire,
all patients within defined populations of participating
countries, who currently suffer from chronic edema for
more than 3 months duration and who are patients
within the health care system.
2. To determine the impact of chronic edema on the lives
of patients using questionnaires as follows:
a. Demographic and disability assessment
b. Health-related quality of life
c. Details of swelling
d. Wound assessment
e. Cancer assessment
3. To estimate the proportion of patients with chronic
edema who also have a wound in the same anatomical
region.
Inclusion criteria
1. The patient is older than 18 years.
2. The patient has swelling for more than 3 months.
3. The patient is able to understand the study as set out in
the information sheet.
4. The patient is able to give informed consent.
Exclusion criteria
1. The patient is unwilling or unable to participate for
whatever reason.
2. The patient is receiving end-of-life care.
3. It is considered not to be in the patient’s best interest
as decided by the lead clinician.
Data collection tools
The Core Tool was the case ascertainment tool. The com-
ponents are shown Table 1. All sites completed the Core Tool.
There was a series of Modular Tools, which were optional.
These included: Demographics and Disability assessment
(WHODAS 2.0), Quality-of-life assessment (LYMQOL +EQ-
5D), Details of swelling, Wound assessment, and Cancer de-
tails. Only a limited number of sites completed the Modular
Tools.
Forty sites in 9 countries participated in the study. These
countries included Australia, Canada, Denmark, France,
Ireland, Italy, Japan, Turkey, and the United Kingdom.
Canadian Site
Site description
The study was conducted at the Parkwood Institute Re-
search, St. Joseph Health Care London, which is part of
Lawson Health Research Institute in London, ON, Canada.
Lawson is the largest hospital-based research institute in Ca-
nada and works in partnership with the Western University.
The mission is to understand the basis of wellness and the
dysfunctions of the body and mind that result from disease.
Our service area includes the South West Local Health
Integration Network (SWLHIN), which covers a large por-
tion of South Western Ontario Canada, from Lake Erie to the
Bruce Peninsula. This area is 21,639 km2, with a population
of 962,539. The health region is geographically large, as it
takes 5 hours to drive from top to bottom. Over half of the
population lives in the Metropolitan London Census Area.
Table 1. Core Tool
Components of Core Tool
Type of facility in which data are collected
Level of obesity
Relevant comorbidities
Mobility
Classification of lymphedema
Lymphedema history
Cellulitis history
Categories of treatment
Site of swelling
Wound area
Access to treatment
Subjective control of swelling
FIG. 1. Age distribution.
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The Parkwood Chronic Wound Management was founded
in 1997 and sees persons with chronic wounds of any eti-
ology. Since 2006, the clinic has maintained an administra-
tive database of clinic patient visits categorized by the
International Classification of Disease code for the most re-
sponsible diagnosis for the visit. Lymphedema is the most
responsible diagnostic code for 670 patients observed from
June 2006 to July 2018. This represents 24% of our clinic
volume. In 2014, a complete audit of 326 lymphedema pa-
tient charts was conducted.5 Our patients at that time were
evenly distributed between males and females, primarily
involved the lower limb and had 7.3 comorbid conditions.
Forty-six percent were morbidly obese.
Aims of the Canadian study
1. To determine the prevalence and functional impact of
chronic edema in the adult population attending a
chronic wound management clinic in the SWLHIN.
2. To determine the impact of chronic edema on the lives
of patients by using five module tools.
3. To estimate the proportion of patients with chronic
edema, who also have a wound in the same anatomical
region.
Methods
The Lymphedema Impact and Prevalence International
(LIMPRINT) study was approved by the Western University
Human Research Ethics Board in March 2016. A contract
was signed between the International Lymphedema Frame-
work and Lawson Health Research Institute in May 2016.
Funding was obtained from the St. Joseph’s Health Care
Foundation. Data collection started in June 2016. Patients
were recruited directly from the Chronic Wound Manage-
ment Clinic. On the clinic visit days, all lymphedema patients
seen between June 6, 2016, and December 11, 2017, were
assessed for eligibility for inclusion into the LIMPRINT
study by the principal investigator. Based on the patient’s
verbal approval, the letter of information was provided for
them to read at home. Permission was granted by the par-
ticipant for the research coordinator to contact them by
FIG. 2. Level of education. Note: None indicates completion of primary education but no secondary graduation diploma.
Table 2. Employment Status
Status
Canada
(%)
International
(%)
Employed full time 16.2 14.3
Employed part time 32.6 3.3
Retired 57.4 28.6
Unemployed looking for work 0 2.4
Not working due to illness 11.8 6.5
Looking after the house 2.9 43.4
Full- or part-time
education or training
1.5 1.3
Other 17.6 2.6
FIG. 3. Mobility.
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telephone at least 2 days after the clinic visit to offer an
appointment for a study visit to the research center. Any
immediate questions were answered. On the study visit day,
the letter of information was explained, and informed consent
was obtained before the start of data collection.
After review of the letter of information and consent sig-
nature, the Core Tool was administered, and the following
Module Tools were also administered by the Research Co-
ordinator: Demographic and Disability Tool, Details of
Swelling Tool, Wound Tool, and Quality-of-Life Tool EQ-5D.
The Filariasis Tool was not administered as lymphatic filari-
asis is not endemic locally. Information used to complete each
tool included patient report, review of clinic notes, and clinical
examination. Most of the data were extracted from clinic notes
in the hospital electronic medical record. Weight and height
were measured in the clinic, and body mass index (BMI) was
automatically calculated by the electronic medical record.
Wound related data were extracted from the most recent clinic
visit, which had occurred in the previous week. The EQ-5D
was independently completed by the patient. Data were en-
tered into a paper-based tool and later transcribed into the
Clindex electronic database. After data entry was closed, all
Clindex data were verified against the paper record.
Results
Internationally, there were 13,016 participants in the Core
Tool, of which 1359 participants completed the Module
Tools. Only Canadian data were available from the Core
Tool, but both Canadian and international data were available
for the Module Tools. From June 2016 to December 2017,
our site enrolled 68 patients in both the Core Tool and the
Module Tools. Of 248 contacted, 180 (73%) patients were
either unable to join or declined to join the study. Main
reasons for non-enrollment were:
1. Travel distance to clinic. (Some patients drive 4 hours
to get to clinic).
2. Language barrier.
3. Unable to participate due to cognitive impairment.
4. Unable to schedule Paratransit.
5. Declined to participate.
Demographics
Gender was relatively evenly balanced with 57% males
and 43% females. Most participants were older than 45 years
(94%). Age distribution is shown in Figure 1. Thirty-two
percent lived alone, whereas 68% lived with a spouse, rela-
tive, or friend. Internationally, fewer people lived alone
(14.8%). Almost two thirds (63%) were the prime financial
supporter of the family, whereas internationally the partici-
pant was less likely to be the prime supporter (24.9%). Sixty-
nine percent owned their home, and 84% owned a car. In-
ternationally, there was comparable home ownership at
77.3%, but car ownership was much less at 58.7%. The
participants were in general well educated as shown in
Figure 2. Mean age at which Canadian participants left
full-time education was 20.4 – 7.4 years compared with
17.4 – 5.6 internationally. Employment status is compared
in Table 2.
Table 3. Causes of Secondary Lymphedema
Condition %
Venous disease 72.06
Obesity 54.41
Noncancer other 14.71
Cancer 8.82
Treatment-related obstruction 8.82
Metastatic disease 8.82
Note: Percentages do not add to 100% as participants had more
than one cause.
FIG. 4. Duration of lymphedema.
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Comorbidities
In our chart audit from 2014,5 we found that our patients had
a mean of 7.3 comorbidities. In this study, 39.1% were found to
have diabetes (38% in the audit), 20.59% with congestive heart
failure and/or ischemic heart disease, 11.76% with neurolog-
ical disorders, and only 2.94% with peripheral artery disease.
Morbid obesity (BMI of >40) accounted for 47.06% of par-
ticipants, which was consistent with 45% in the chart audit.
Very few participants had problems with upper limb mobility
(4%), but lower limb mobility issues affected a significant
number of participants, as shown in Figure 3.
Lymphedema characteristics
Only 7.35% were deemed to have primary lymphedema,
with secondary lymphedema accounting for 92.65% of cases.
Secondary causes are shown in Table 3. Most participants
had lymphedema for more than 5 years (Fig. 4). While
72.06% reported at least on episode of cellulitis in the past,
only 10.9% reported hospitalization in the past year. Only
two people reported more than one hospitalization.
Location and details of swelling
No participants had swelling of the head and neck or
genitals. Three patients had swelling of the left arm, but only
two had swelling extend to the fingers. Three participants had
swelling of the right arm, but the upper arm was involved in
only one. Most participants reported no swelling in the
midline or trunk. Four participants reported buttock swelling.
FIG. 5. Comparison of location of lower extremity edema.
Table 4. Details of Swelling
Variable Canada (%) International (%)
Pitting
Yes 67.7 58.1
No 32.4 41.9
Tissue
Soft 79.4 71.5
Hard 20.6 28.5
Shape distortion
Yes 26.5 35.2
No 73.5 64.8
Has patient been told reason
Yes 77.9 62.2
No 22.1 37.8
Limb involved
Arm only 0 37.4
Leg 95.6 59.2
Both 4.4 3.4
Stemmers sign positive
Right hand 66.7 21.5
Left hand 66.7 22.4
Right foot 80.7 47.2
Left foot 83.8 48.7
Severity
ISL stage I 11.8 27.9
ISL stage II 66.2 58.7
ISL stage III 22.1 13.4
ISL, International Society of Lymphology.
Table 5. Cancer Type
Canada
(n = 8), n (%)
International
(n= 816), n (%)
Bladder cancer 1 (12.5) 3 (0.4)
Breast cancer 1 (12.5) 633 (77.6)
Cervical cancer 2 (25.0) 42 (5.1)
Colorectal cancer 1 (12.5) 5 (0.6)
Endometrial cancer 0 77 (9.4)
Head and neck cancer 1 (12.5) 2 (0.2)
Melanoma cancer 1 (12.5) 7 (0.9)
Ovarian cancer 0 29 (3.6)
Vulval cancer 0 2 (0.2)
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The majority of patients seen in our center had multifactorial
lower extremity chronic edema. Location of lower limb
swelling is shown in Figure 5. Comparison between Canadian
and international swelling details data is shown in Table 4.
Lymphedema and cancer
The Canadian site sees few cancer patients as these people are
followed primarily in cancer treatment centers. For comparison
with international and Canadian data, see Tables 5 and 6.
Treatments
Treatments received are detailed in Table 7.
Wounds and lymphedema
In this study, 39.71% of the Canadian participants had a
wound, which is compared with 64% found in the 2014 chart.
Nurses in both Canada and internationally are the primary
wound care providers, with more than 85% indicating that a
nurse was involved in their care. In Canada, all nursing care was
delivered in the community, whereas internationally most nur-
ses were hospital based. Self-care and informal caregivers were
involved in one third of cases. Three quarters had three or fewer
wounds. In Canada, only one wound was reported as a pressure
ulcer compared with 13% internationally. There were no sur-
gical wounds reported from Canada, whereas internationally
67.6% of 651 wounds were reported as surgical, but few of these
were open and most had been closed primarily. In Canada, 26 of
27 wounds were lower extremity and 84.6% were considered
venous. Exudate levels are compared in Figure 6. Despite that
exudate levels were higher in Canada, only 47.6 considered the
level problematic as opposed to 79% internationally. Wound
size in Canada was much smaller with 85.2% being <10 cm2
compared with 18.4% internationally. Possible infection rates
were more than double at 29.6% in Canada as opposed to 11.3%
internationally. Wound durations were different. In Canada,
almost 60% had a wound duration >6 months, whereas only
25.4% in the international data set had a duration >6 months.
Dressing change frequencies are compared in Figure 7.
Access to care
In our Local Health Integration Network, all treatments are
fully funded for all patients except manual lymphatic drain-
age (MLD). Limited funding is available for physiotherapy
through home and community care primarily for exercise
programs. Pneumatic compression pumps are funded only for
primary lymphedema. Despite this, 71.79% of males and
51.72% of females responded that their entire care was
covered. This gender difference reached statistical signifi-
cance at p = 0.0895. Few participants indicated that travel
distance was a barrier to specialist care (males = 5.13%, fe-
males = 6.90%). Only one male and one female indicated that
lack of transport was barrier. No patients were hospitalized.
Only one female reported that her lymphedema prevented her
from being discharged from home and community care.
Impact of lymphedema
A relatively low percentage of Canadian participants, 20.6%,
responded that their lymphedema affected their work life lead-
ing to a change of job or educational activities. The same per-
centage reported reduced income. More than 75% continued to
work. Those who stopped work had done so a mean of 12.5 years
previously. 26.8% reported that family income was adversely
affected by their swelling. Results of the WHODAS 2.0 showed
that the most adversely affected domains were standing for more
than 30 minutes, 48.5% severe/extreme, and walking long dis-
tance such as 1 km, 75% severe/extreme. Difficulties were re-
ported as present for an average of 18.3–13.1 days out of 30. On
average out of 30 days, participants cut back on activities for
9.0– 10.8 days and were unable to carry out normal activities
for 5.8–9.2 days. The overall WHODAS score for the group
was a mean of 32.8–22.2, where 0 is no disability and 100 is
maximum.
The EQ-5D detailed scores are shown in Table 8. Overall, the
participants rated their quality of life at mean of 0.51–0.33,
where 1.0 is the best quality of life. When asked to use a visual
analogue scale to rate their quality of life on that day, the mean
score was 61.6– 19.9, where 100 is the best quality of life score.
The international scores were similar at 0.57–0.33 and
61.8–20.6. The final quality-of-life tool used was the LYM-
QOL. The LYMQOL overall scores are shown in Figure 8.
Canadian data are mostly related to the lower extremity. In-
dividual domains most affected were mobility and some activ-
ities of daily living. Least affected were the emotional domains
with*80% reporting little or no effect. International data are
not compared as it related mostly to the upper extremity.
Discussion
This study gives an estimate of the prevalence of lymphedema
in the defined population of adults attending a chronic wound
Table 6. Time to Onset of Swelling
After Cancer Treatment
Canada
(n= 8/68),
n (%)
International
(n = 816/1359),
n (%)
<3 months 3 (37.5) 160 (19.7)
3–11 months 0 261 (32.1)
1–5 years 3 (37.5) 279 (34.4)
6–9 years 1 (12.5) 44 (5.4)
10+ years 1 (12.5) 50 (6.2)
Unknown 0 10 (1.2)
Not applicable 8 (1.0)
Table 7. Treatment Details
Treatment %
Skin care advice 97.06
Wound dressings 95.59
Antibiotics 85.29
Massage 1.47
Physiotherapy 1.47
Compression garments 76.47
Multilayer bandaging 85.29
Pneumatic compression pumps 1.47
Debulking lipedema surgery 0
Exercise advice 79.41
Cellulitis advice 76.47
Psychological support 1.47
Other complex decongestive therapy 1.47
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management clinic, which is a specialist referral center for a
population of just under 1 million people. No other center pro-
vides a comprehensive assessment and diagnosis. The clinic
provides recommendations for care, education, and monitoring
of care. At the time of the study, lymphedema patients re-
presented 24% of the clinic volume. The study results do provide
a clear picture of the characteristics of these patients and the
impact lymphedema has on their lives. The small sample size
and the large number of patients who were unable to participate
is a weakness of the study, but the results are completely con-
sistent with a previous chart audit conducted in 2014 of 326
patients.5 This suggests that it is a representative sample. It is
unusual to see a higher proportion of males to females in pub-
lished prevalence data. This relates to the location of the lym-
phedema primarily in the lower limbs in this patient population.
The involvement of the lower limb also accounts for the sig-
nificant percentage, 62%, of mobility issues, as shown in Table 5.
The causes of secondary lymphedema in this study as shown in
Table 6 are consistent with chart audit, 72% versus 73% venous.
Table 7 shows that over half of the participants had their lym-
phedema for more than 10 years. Many participants had chronic
swelling for many years before receiving a diagnosis. Table 9
FIG. 6. Comparison of exudate levels.
FIG. 7. Dressing change frequency.
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shows that the difference between the Canadian and international
data is explained by the predominance of lower leg edema in the
Canadian participants. This also demonstrates that lower limb
lymphedema is associated with more advanced stages of lym-
phedema, 88.3% Stage II or greater as opposed to 72.1%. Table 5
clearly demonstrates that the international data are heavily
skewed toward breast cancer survivors and hence the emphasis
on arm morbidity. Caution in interpreting these data is re-
commended given that they represent the smaller subset of
participants who completed the Module Tools. In this study,
39.71% of participants had an open wound compared with 64%
in the chart audit. The difference relates to the time frame. In the
study, it is the percentage with a wound at the study visit, whereas
in the audit, it was any history of a wound. Again, the location,
duration, and severity of wounds are related to upper versus
lower extremity location. Lower extremity wounds are generally
more complex and are associated with many more comorbid
conditions especially edema causing conditions, such as
Table 8. EQ-5D Scores
Domain Question n (%)
Mobility I have no problems in walking about 16 (23.9)
I have some problems walking about 51 (76.1)
I am confined to a bed 0
Missing 1
Self-care I have no problems with self-care 31 (45.6)
I have some problems washing or dressing myself 34 (50.0)
I am unable to wash or dress myself 3 (4.4)
Missing 0
Usual activities I have no problems with performing my usual activities 20 (29.4)
I have some problems with performing my usual activities 42 (61.8)
I am unable to perform my usual activities 6 (8.8)
Missing 0
Pain/discomfort I have no pain or discomfort 13 (19.1)
I have some moderate pain or discomfort 43 (63.2)
I have extreme pain or discomfort 12 (17.7)
Missing 0
Anxiety/depression I am not anxious or depressed 36 (52.9)
I am moderately anxious or depressed 27 (39.7)
I am extremely anxious or depressed 5 (7.4)
Missing 0
FIG. 8. Overall quality-of-life score.
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congestive heart failure, liver failure, and renal failure. They are
far more prone to infection. Location of provision of care was
different and related to international data being heavily weighted
toward post breast cancer surgery. Care was predominantly
hospital based. In Canada, it was based in the community and is
fully funded by the provincial health care system. The difference
in dressing change frequency, shown in Figure 7, relates to
standard of care for dressing changes being two to three times
weekly in home care. The statistically significant difference
between males and females in whether their care was fully
funded was surprising given that all care is funded except for
MLD and intermittent pneumatic compression pumps. It may
relate to females having greater expectation that the MLD should
be covered.
The overall WHODAS score is relatively low at 32.8 given
that the normative value for ages 55–64 years is 3.4– 5.7.6 It is
not surprising that most disability was related to standing and
walking since 95.6% had lower lymphedema. The EQ-5D
overall score of 0.51– 0.33 is somewhat lower than that obtained
from the visual analogue scale of 61.1– 19.9 but is within the
standard deviation. The EQ-5D does not ask specifically about
lymphedema but is an overall quality-of-life score and can be
affected by other comorbid conditions. The LYMQOL, how-
ever, does ask specifically about quality of life as it relates to
living with lymphedema. When the scores are averaged the mean
comes to 6.2, which is quite consistent with the EQ-5D scores.
Interestingly, the comparison between international and
Canadian data reflects that between two Canadian clinics. We
have previously discussed our data.5 In 2017, Shallwani
et al.7 reported on an audit of 429 patients observed in their
lymphedema clinic in Montreal in the previous 2 years. The
comparison is shown in Table 9. Not unlike the international
data, Dr. Towers sees predominantly female patients with
breast cancer-related arm morbidity. It is predominantly
unilateral. Lower limb lymphedema patients tend to be rel-
atively evenly divided between males and females, to have
bilateral involvement and to have more complex chronic
edema. We are seeing more patients with lymphedema post
hip and knee replacements. With the aging population and
growing rates of obesity in developed countries, we likely to
see increasing rates of lower extremity lymphedema.
Conclusion
This study reports on the characteristics of a defined popu-
lation of lymphedema patients being treated in an outpatient
chronic wound management clinic. These patients have bal-
anced gender representation and have predominantly lower
limb lymphedema, which is usually bilateral and complex.
Over one third have a concurrent lower extremity wound and
they are prone to cellulitis. While upper limb lymphedema after
breast cancer surgery has received widespread attention, lower
extremity lymphedema is in general poorly recognized. With
increasing risk factors such advancing age, decreased mobility,
longstanding venous disease, hip and knee replacements, and
growing rates of obesity, this problem is likely to become more
prevalent. Early recognition and treatment will become im-
portant to reduce morbidity. Data such as this and the wider
LIMPRINT study are important tools to advocate for wider
recognition and funding of treatment by health care systems.
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Table 9. Comparison of Two Canadian
Lymphedema Clinic Chart Audits
Characteristic Shallwani et al.7 Wang and Keast5
Mean age, years 61.4 At diagnosis = 66.8
Female 85% 52.1%
Male 15% 47.9%
Cancer 81% 10%
Primary 7% 4%
Secondary 93% 96%
Upper body 51% 1.2%
Lower body 45% 99.7%
Unilateral 74% 17%
Bilateral 25% 83%
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